| Literature DB >> 27727190 |
Ross Lawrenson1, Chunhuan Lao2, Mark Elwood3, Charis Brown4, Diana Sarfati5, Ian Campbell6.
Abstract
Many rural communities have poor access to health services due to a combination of distance from specialist services and a relative shortage of general practitioners. Our aims were to compare the characteristics of urban and rural women with breast cancer in New Zealand, to assess breast cancer-specific and all-cause survival using the Kaplan-Meier method and Cox proportional hazards model, and to assess whether the impact of rurality is different for Māori and New Zealand (NZ) European women. We found that rural women tended to be older and were more likely to be Māori. Overall there were no differences between urban and rural women with regards their survival. Rural Māori tended to be older, more likely to be diagnosed with metastatic disease and less likely to be screen detected than urban Māori. Rural Māori women had inferior breast cancer-specific survival and all-cause survival at 10 years at 72.1% and 55.8% compared to 77.9% and 64.9% for urban Māori. The study shows that rather than being concerned that more needs to be done for rural women in general it is rural Māori women where we need to make extra efforts to ensure early stage at diagnosis and optimum treatment.Entities:
Keywords: Māori; breast cancer; equity; rural; survival; urban
Mesh:
Year: 2016 PMID: 27727190 PMCID: PMC5086739 DOI: 10.3390/ijerph13101000
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Characteristics of urban and rural women.
| Characteristics | Rural | Urban | Total | ||||
|---|---|---|---|---|---|---|---|
| <40 | 126 | 5.3% | 669 | 6.8% | 795 | 6.5% | |
| 40–49 | 401 | 17.0% | 2263 | 22.9% | 2664 | 21.7% | |
| 50–59 | 626 | 26.5% | 2689 | 27.2% | 3315 | 27.1% | |
| 60–69 | 600 | 25.4% | 2233 | 22.6% | 2833 | 23.1% | |
| 70–79 | 364 | 15.4% | 1178 | 11.9% | 1542 | 12.6% | |
| 80+ | 247 | 10.4% | 853 | 8.6% | 1100 | 9.0% | |
| I | 997 | 42.2% | 4291 | 43.4% | 5288 | 43.2% | |
| II | 890 | 37.6% | 3643 | 36.9% | 4533 | 37.0% | |
| III | 345 | 14.6% | 1514 | 15.3% | 1859 | 15.2% | |
| IV | 132 | 5.6% | 437 | 4.4% | 569 | 4.6% | |
| 1 | 557 | 25.3% | 2270 | 24.1% | 2827 | 24.4% | |
| 2 | 1113 | 50.5% | 4281 | 45.5% | 5394 | 46.5% | |
| 3 | 535 | 24.3% | 2850 | 30.3% | 3385 | 29.2% | |
| Unknown | 159 | 484 | 643 | ||||
| 0–20 | 1123 | 51.7% | 4726 | 50.3% | 5849 | 50.5% | |
| 20+ | 1050 | 48.3% | 4674 | 49.7% | 5724 | 49.5% | |
| Unknown | 191 | 485 | 676 | ||||
| Not screen detected | 1458 | 61.7% | 6084 | 61.5% | 7542 | 61.6% | |
| Screen detected | 906 | 38.3% | 3801 | 38.5% | 4707 | 38.4% | |
| ER and PR negative | 395 | 17.1% | 1840 | 19.0% | 2235 | 18.7% | |
| ER and/or PR positive | 1910 | 82.9% | 7819 | 81.0% | 9729 | 81.3% | |
| Unknown | 59 | 226 | 285 | ||||
| NZ European | 1932 | 82.2% | 6943 | 71.2% | 8875 | 73.3% | |
| Māori | 311 | 13.2% | 844 | 8.7% | 1155 | 9.5% | |
| Pacific | 38 | 1.6% | 759 | 7.8% | 797 | 6.6% | |
| Asian | 47 | 2.0% | 920 | 9.4% | 967 | 8.0% | |
| Others | 22 | 0.9% | 285 | 2.9% | 307 | 2.5% | |
| Unknown | 14 | 134 | 148 | ||||
| 2364 | 100% | 9885 | 100% | 12,249 | 100% | ||
ER: Estrogen receptor; RP: Progesterone receptor; NZ: New Zealand.
Urban and rural women Māori and NZ European.
| Characteristics | Māori | NZ European | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rural | Urban | Total | Rural | Urban | Total | |||||||
| <40 | 23 | 7.4% | 74 | 8.8% | 97 | 8.4% | 95 | 4.9% | 407 | 5.9% | 502 | 5.7% |
| 40–49 | 66 | 21.2% | 238 | 28.2% | 304 | 26.3% | 303 | 15.7% | 1391 | 20.0% | 1694 | 19.1% |
| 50–59 | 100 | 32.2% | 264 | 31.3% | 364 | 31.5% | 488 | 25.3% | 1796 | 25.9% | 2284 | 25.7% |
| 60–69 | 82 | 26.4% | 183 | 21.7% | 265 | 22.9% | 491 | 25.4% | 1650 | 23.8% | 2141 | 24.1% |
| 70–79 | 29 | 9.3% | 72 | 8.5% | 101 | 8.7% | 324 | 16.8% | 926 | 13.3% | 1250 | 14.1% |
| 80+ | 11 | 3.5% | 13 | 1.5% | 24 | 2.1% | 231 | 12.0% | 773 | 11.1% | 1004 | 11.3% |
| I | 112 | 36.0% | 315 | 37.3% | 427 | 37.0% | 837 | 43.3% | 3136 | 45.2% | 3973 | 44.8% |
| II | 112 | 36.0% | 313 | 37.1% | 425 | 36.8% | 726 | 37.6% | 2546 | 36.7% | 3272 | 36.9% |
| III | 53 | 17.0% | 162 | 19.2% | 215 | 18.6% | 279 | 14.4% | 1003 | 14.4% | 1282 | 14.4% |
| IV | 34 | 10.9% | 54 | 6.4% | 88 | 7.6% | 90 | 4.7% | 258 | 3.7% | 348 | 3.9% |
| 1 | 56 | 19.7% | 181 | 22.5% | 237 | 21.7% | 469 | 26.0% | 1673 | 25.4% | 2142 | 25.5% |
| 2 | 158 | 55.6% | 384 | 47.6% | 542 | 49.7% | 905 | 50.1% | 3009 | 45.6% | 3914 | 46.6% |
| 3 | 70 | 24.6% | 241 | 29.9% | 311 | 28.5% | 432 | 23.9% | 1911 | 29.0% | 2343 | 27.9% |
| Unknown | 27 | 38 | 65 | 126 | 350 | 476 | ||||||
| 0–20 | 130 | 48.0% | 322 | 40.6% | 452 | 42.4% | 945 | 52.9% | 3497 | 52.9% | 4442 | 52.9% |
| 20+ | 141 | 52.0% | 472 | 59.4% | 613 | 57.6% | 843 | 47.1% | 3109 | 47.1% | 3952 | 47.1% |
| Unknown | 40 | 50 | 90 | 144 | 337 | 481 | ||||||
| Not screen detected | 208 | 66.9% | 538 | 63.7% | 746 | 64.6% | 1170 | 60.6% | 4209 | 60.6% | 5379 | 60.6% |
| Screen detected | 103 | 33.1% | 306 | 36.3% | 409 | 35.4% | 762 | 39.4% | 2734 | 39.4% | 3496 | 39.4% |
| ER and PR negative | 55 | 18.0% | 131 | 15.8% | 186 | 16.4% | 324 | 17.2% | 1275 | 18.8% | 1599 | 18.4% |
| ER and/or PR positive | 251 | 82.0% | 696 | 84.2% | 947 | 83.6% | 1558 | 82.8% | 5518 | 81.2% | 7076 | 81.6% |
| Unknown | 5 | 17 | 22 | 50 | 150 | 200 | ||||||
| 311 | 100% | 844 | 100% | 1155 | 100% | 1932 | 100% | 6943 | 100% | 8875 | 100% | |
ER: Estrogen receptor; RP: Progesterone receptor; NZ: New Zealand.
5-year and 10-year breast cancer-specific survival and all-cause survival by Kaplan–Meier method.
| Groups | 5-Year (95% CI) | 10-Year (95% CI) | Log Rank Test ( | ||
|---|---|---|---|---|---|
| Rural women | 86.6% | (85.1%–88.1%) | 81.5% | (79.6%–83.4%) | 0.211 |
| Urban women | 88.0% | (87.3%–88.7%) | 82.5% | (81.5%–83.4%) | |
| Rural Māori women | 78.3% | (73.2%–83.5%) | 72.1% | (65.8%–78.5%) | 0.072 |
| Urban Māori women | 84.1% | (81.4%–86.8%) | 77.9% | (74.2%–81.5%) | |
| Rural European women | 87.9% | (86.3%–89.4%) | 82.7% | (80.7%–84.8%) | 0.605 |
| Urban European women | 88.6% | (87.8%–89.4%) | 83.0% | (81.9%–84.1%) | |
| Rural women | 80.6% | (78.9%–82.3%) | 67.8% | (65.4%–70.2%) | 0.007 |
| Urban women | 82.7% | (81.9%–83.4%) | 71.2% | (70.1%–72.4%) | |
| Rural Māori women | 71.6% | (66.2%–77.0%) | 55.8% | (48.2%–63.3%) | 0.017 |
| Urban Māori women | 77.9% | (74.9%–80.9%) | 64.9% | (60.6%–69.2%) | |
| Rural European women | 81.9% | (80.0%–83.7%) | 69.0% | (66.4%–71.6%) | 0.394 |
| Urban European women | 82.0% | (81.1%–83.0%) | 70.3% | (69.0%–71.7%) | |
Hazard ratio for mortality estimated by Cox proportional hazards model.
| Groups | Unadjusted Hazard Ratio (95% CI) | Adjusted Hazard 1 Ratio (95% CI) | ||
|---|---|---|---|---|
| Rural women compared with urban women | 1.08 | (0.96–1.22) | 1.01 | (0.87–1.17) |
| Rural Māori women compared with urban Māori women | 1.31 | (0.97–1.76) | 1.47 | (1.00–2.16) |
| Rural European women compared with urban European women | 1.04 | (0.90–1.19) | 0.94 | (0.79–1.10) |
| Rural women compared with urban women | 1.13 | (1.03–1.24) * | 1.04 | (0.94–1.16) |
| Rural Māori women compared with urban Māori women | 1.33 | (1.05–1.68) * | 1.43 | (1.08–1.91) * |
| Rural European women compared with urban European women | 1.05 | (0.94–1.16) | 0.90 | (0.80–1.02) |
1 Adjusted for age, (ethnicity), cancer stage, tumour size, grade, hormonal status (ERPR), year of diagnosis, mode of detection and comorbidity. * p-Value < 0.05.